IN2015DN01967A - - Google Patents

Info

Publication number: IN2015DN01967A
Authority: IN; India
Prior art keywords: antibody; compared; reduced immunogenicity; anti tnf; reference antibody
Prior art date: 2012-09-19

Application number

Other languages

English (en)

Inventor

Fiona A Harding

Olivia Jennifer Razo

Original Assignee

Abbvie Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-09-19

Filing date

2013-09-18

Publication date

2015-08-14

2013-09-18 Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc

2015-08-14 Publication of IN2015DN01967A publication Critical patent/IN2015DN01967A/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pathology (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

IN1967DEN2015 2012-09-19 2013-09-18 IN2015DN01967A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261703170P	2012-09-19	2012-09-19
PCT/US2013/060480 WO2014047222A2 (fr)	2012-09-19	2013-09-18	Procédés d'identification d'anticorps ayant une immunogénicité réduite

Publications (1)

Publication Number	Publication Date
IN2015DN01967A true IN2015DN01967A (fr)	2015-08-14

Family

ID=49304336

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN1967DEN2015 IN2015DN01967A (fr)	2012-09-19	2013-09-18

Country Status (28)

Country	Link
US (1)	US9279016B2 (fr)
EP (2)	EP3211006A3 (fr)
JP (1)	JP2015537190A (fr)
KR (1)	KR20150056788A (fr)
CN (1)	CN104704000A (fr)
AU (1)	AU2013318147B2 (fr)
BR (1)	BR112015005857A2 (fr)
CA (1)	CA2885422A1 (fr)
CY (1)	CY1118893T1 (fr)
DK (1)	DK2897978T3 (fr)
ES (1)	ES2621285T3 (fr)
HK (1)	HK1211306A1 (fr)
HR (1)	HRP20170937T1 (fr)
HU (1)	HUE032569T2 (fr)
IL (1)	IL237833A0 (fr)
IN (1)	IN2015DN01967A (fr)
LT (1)	LT2897978T (fr)
MX (1)	MX2015003541A (fr)
NZ (1)	NZ705606A (fr)
PL (1)	PL2897978T3 (fr)
PT (1)	PT2897978T (fr)
RS (1)	RS56093B1 (fr)
RU (1)	RU2648141C2 (fr)
SG (1)	SG11201502094TA (fr)
SI (1)	SI2897978T1 (fr)
SM (1)	SMT201700255T1 (fr)
TW (1)	TWI519646B (fr)
WO (1)	WO2014047222A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106478802B (zh) *	2016-10-11	2019-08-09	浙江省人民医院	TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
EP3558363A1 (fr)	2016-12-21	2019-10-30	Amgen Inc.	Formulations d'anticorps anti-tnf alpha
JP7473339B2 (ja) *	2017-03-07	2024-04-23	エフ．ホフマン－ラロシュアーゲー	代替の抗原特異的抗体変異体を発見するための方法
TW202039554A (zh) *	2018-12-19	2020-11-01	瑞士商諾華公司	抗ＴＮＦ－α抗體
CN114401988A (zh) *	2019-07-09	2022-04-26	国家生物技术研究所公司	具有降低的免疫原性的抗体
EP4037699A1 (fr)	2019-09-30	2022-08-10	SciRhom GmbH	Liants protéiques à des épitopes d'irhom2
FR3104582A1 (fr) *	2019-12-17	2021-06-18	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) *	2019-12-31	2023-06-16	科美博阳诊断技术(上海)有限公司	一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (fr) *	2020-01-20	2021-07-29	Bio-Thera Solutions, Ltd.	Procédés, modèles et systèmes liés à l'immunogénicité d'anticorps
KR102568430B1 (ko) *	2020-11-16	2023-08-24	바디텍메드(주)	항 약물 항체의 신속 검출 방법
EP4301778A1 (fr)	2021-03-01	2024-01-10	SciRhom GmbH	Anticorps humanisés contre irhom2
WO2022207652A1 (fr)	2021-03-29	2022-10-06	Scirhom Gmbh	Méthodes de traitement utilisant des liants protéiques pour des épitopes irhom2
WO2022214664A1 (fr)	2021-04-09	2022-10-13	Philogen S.P.A.	Mutant amélioré d'interféron-gamma
WO2024023246A1 (fr)	2022-07-28	2024-02-01	Philogen S.P.A.	Anticorps se liant à pd1
WO2024033362A1 (fr)	2022-08-08	2024-02-15	Atb Therapeutics	Anticorps humanisés dirigés contre cd79b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
EP0189330B1 (fr)	1985-01-25	1992-12-02	The Kitasato Institute	Antibiotiques antitumoraux et leur production
US5264357A (en)	1985-05-24	1993-11-23	Genentech, Inc.	Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en)	1991-07-17	1993-11-23	The Scripps Research Institute	Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6258562B1 (en) *	1996-02-09	2001-07-10	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en)	1998-07-30	2004-09-07	Solexa Ltd.	Arrayed biomolecules and their use in sequencing
AR021833A1 (es)	1998-09-30	2002-08-07	Applied Research Systems	Metodos de amplificacion y secuenciacion de acido nucleico
WO2000029584A1 (fr)	1998-11-18	2000-05-25	Genentech, Inc.	Variants d'anticorps a affinite de liaison superieure par rapport aux anticorps d'origine
US7211390B2 (en)	1999-09-16	2007-05-01	454 Life Sciences Corporation	Method of sequencing a nucleic acid
EP1218543A2 (fr)	1999-09-29	2002-07-03	Solexa Ltd.	Sequen age de polynucleotides
US6686168B1 (en)	1999-11-04	2004-02-03	Zymogenetics, Inc.	Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) *	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6897023B2 (en)	2000-09-27	2005-05-24	The Molecular Sciences Institute, Inc.	Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en)	2001-04-30	2005-04-26	Seattle Genetics, Inc.	Pentapeptide compounds and uses related thereto
US6956114B2 (en)	2001-10-30	2005-10-18	'454 Corporation	Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en)	2001-12-04	2006-06-06	Solexa Limited	Labelled nucleotides
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
WO2004029284A2 (fr)	2002-09-30	2004-04-08	Protein Design Labs, Inc.	Generation efficace de lignees cellulaires d'expression stable par utilisation de genes rapporteurs homeostatiques pouvant etre soumis a notation
EP2478912B1 (fr)	2003-11-06	2016-08-31	Seattle Genetics, Inc.	Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
WO2005123780A2 (fr)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
TWI439284B (zh) *	2004-04-09	2014-06-01	Abbvie Biotechnology Ltd	用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7632497B2 (en)	2004-11-10	2009-12-15	Macrogenics, Inc.	Engineering Fc Antibody regions to confer effector function
DK1951759T3 (da)	2005-11-12	2010-05-10	Lilly Co Eli	Anti-EGFR-antistoffer
JP5759722B2 (ja) *	2007-08-28	2015-08-05	アッヴィバイオテクノロジーリミテッド	アダリムマブの結合蛋白質を含む組成物及び方法
WO2009059235A2 (fr)	2007-11-01	2009-05-07	Facet Biotech Corporation	Vecteurs de présentation d'immunoglobulines
RU2595379C2 (ru) *	2009-04-16	2016-08-27	АббВай Биотерапеутикс Инк.	АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
GB0909904D0 (en) *	2009-06-09	2009-07-22	Affitech As	Product
SG183867A1 (en) *	2010-03-11	2012-10-30	Rinat Neuroscience Corp	ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2012020038A1 (fr) *	2010-08-13	2012-02-16	Roche Glycart Ag	Anticorps anti-ténascine c a2 et procédés d'utilisation
EA201300470A1 (ru) *	2010-10-20	2014-05-30	Оксфорд Байотерепьютикс Лтд.	Антитела

2013
- 2013-09-18 PT PT137734745T patent/PT2897978T/pt unknown
- 2013-09-18 EP EP17154662.5A patent/EP3211006A3/fr not_active Withdrawn
- 2013-09-18 WO PCT/US2013/060480 patent/WO2014047222A2/fr active Application Filing
- 2013-09-18 HU HUE13773474A patent/HUE032569T2/en unknown
- 2013-09-18 CN CN201380048863.XA patent/CN104704000A/zh active Pending
- 2013-09-18 RU RU2015111671A patent/RU2648141C2/ru not_active IP Right Cessation
- 2013-09-18 PL PL13773474T patent/PL2897978T3/pl unknown
- 2013-09-18 EP EP13773474.5A patent/EP2897978B1/fr active Active
- 2013-09-18 US US14/030,977 patent/US9279016B2/en not_active Expired - Fee Related
- 2013-09-18 DK DK13773474.5T patent/DK2897978T3/en active
- 2013-09-18 BR BR112015005857A patent/BR112015005857A2/pt active Search and Examination
- 2013-09-18 ES ES13773474.5T patent/ES2621285T3/es active Active
- 2013-09-18 MX MX2015003541A patent/MX2015003541A/es unknown
- 2013-09-18 IN IN1967DEN2015 patent/IN2015DN01967A/en unknown
- 2013-09-18 SG SG11201502094TA patent/SG11201502094TA/en unknown
- 2013-09-18 JP JP2015533163A patent/JP2015537190A/ja active Pending
- 2013-09-18 AU AU2013318147A patent/AU2013318147B2/en not_active Ceased
- 2013-09-18 RS RS20170609A patent/RS56093B1/sr unknown
- 2013-09-18 CA CA2885422A patent/CA2885422A1/fr not_active Abandoned
- 2013-09-18 SM SM20170255T patent/SMT201700255T1/it unknown
- 2013-09-18 LT LTEP13773474.5T patent/LT2897978T/lt unknown
- 2013-09-18 TW TW102134040A patent/TWI519646B/zh not_active IP Right Cessation
- 2013-09-18 KR KR1020157007286A patent/KR20150056788A/ko not_active Withdrawn
- 2013-09-18 NZ NZ705606A patent/NZ705606A/en not_active IP Right Cessation
- 2013-09-18 SI SI201330608A patent/SI2897978T1/sl unknown
2015
- 2015-03-19 IL IL237833A patent/IL237833A0/en unknown
- 2015-12-09 HK HK15112156.8A patent/HK1211306A1/xx not_active IP Right Cessation
2017
- 2017-04-11 CY CY20171100428T patent/CY1118893T1/el unknown
- 2017-06-20 HR HRP20170937TT patent/HRP20170937T1/hr unknown

Also Published As

Publication number	Publication date
NZ705606A (en)	2018-05-25
HUE032569T2 (en)	2017-09-28
DK2897978T3 (en)	2017-05-15
KR20150056788A (ko)	2015-05-27
EP3211006A2 (fr)	2017-08-30
CN104704000A (zh)	2015-06-10
CY1118893T1 (el)	2018-01-10
HRP20170937T1 (hr)	2017-11-03
AU2013318147A1 (en)	2015-03-19
SG11201502094TA (en)	2015-04-29
EP2897978A2 (fr)	2015-07-29
MX2015003541A (es)	2015-10-26
US9279016B2 (en)	2016-03-08
PL2897978T3 (pl)	2017-08-31
JP2015537190A (ja)	2015-12-24
CA2885422A1 (fr)	2014-03-27
RU2015111671A (ru)	2016-11-10
IL237833A0 (en)	2015-05-31
WO2014047222A3 (fr)	2014-10-23
RU2648141C2 (ru)	2018-03-22
WO2014047222A2 (fr)	2014-03-27
PT2897978T (pt)	2017-05-22
RS56093B1 (sr)	2017-10-31
EP2897978B1 (fr)	2017-03-22
WO2014047222A9 (fr)	2014-06-26
SI2897978T1 (sl)	2017-05-31
EP3211006A3 (fr)	2017-11-08
HK1211306A1 (en)	2016-05-20
ES2621285T3 (es)	2017-07-03
US20140227251A1 (en)	2014-08-14
TW201418469A (zh)	2014-05-16
AU2013318147B2 (en)	2018-01-04
SMT201700255T1 (it)	2017-07-18
LT2897978T (lt)	2017-06-12
BR112015005857A2 (pt)	2017-08-08
TWI519646B (zh)	2016-02-01

Publication	Publication Date	Title
IN2015DN01967A (fr)	2015-08-14
IL271697A (en)	2020-02-27	Antibodies against CXCR3
HK1206364A1 (en)	2016-01-08	Methods for improving diaphragm function
IN2014CN02639A (fr)	2015-08-07
IL228001B (en)	2018-06-28	Antibodies to 70cd
AU2013316100A1 (en)	2015-04-02	Antibody evolution immunogens
EP2855529A4 (fr)	2015-12-09	Anticorps anti-facteur b humaneered
GB201207235D0 (en)	2012-06-06	Fuel pump assembly
ZA201406703B (en)	2016-02-24	Improved injections
EP2877886A4 (fr)	2016-04-13	Moteur optique
EP2804876A4 (fr)	2016-02-24	Nouveaux anticorps
GB201212703D0 (en)	2012-08-29	Transactional account repository
EP2695133A4 (fr)	2014-08-27	Identifier une similarité
GB201218066D0 (en)	2012-11-21	Optoelectronic assembly
LT2750136T (lt)	2018-12-10	Kuro rinklė
UA72478U (ru)	2012-08-27	Применение полентара как средства фригопротекторного действия
GB201202794D0 (en)	2012-04-04	Fuel economy patent abstract
UA80618U (en)	2013-06-10	Use of n-steroylethanolamine as radiomodifier